BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced the submission of an ANDA drug product developed jointly with Sofgen Pharmaceuticals. Akorn is requesting an Expedited Review of the ANDA drug product, which is identical to the reference listed drug (RLD). Akorn entered into the definitive exclusive development and supply agreement with Sofgen on August 10, 2006 in order to commercialize an ANDA drug product. The drug is indicated for the treatment of nausea and vomiting associated with cancer chemotherapy. The current market size of the drug is approximately $180 million, and represents a 40% market size increase since the signing of the definitive agreement.
